Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Auteurs : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A
Année : 2022
Journal : Cells
Volume : 11

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.

Auteurs : Spira A, Awada A, Isambert N, Lorente D, Penel N, Zhang Y, Ojalvo LS, Hicking C, Rolfe PA, Ihling C, Dussault I, Locke G, Borel C
Année : 2022
Journal : Front Oncol
Volume : 12
Pages : 981940

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

Auteurs : Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E
Année : 2022
Journal : Liver Cancer
Volume : 11
Pages : 268-277

Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.

Auteurs : Cailleux F, Agostinetto E, Lambertini M, Rothé F, Wu HT, Balcioglu M, Kalashnikova E, Vincent D, Viglietti G, Gombos A, Papagiannis A, Veys I, Awada A, Sethi H, Aleshin A, Larsimont D, Sotiriou C, Venet D, Ignatiadis M
Année : 2022
Journal : JCO Precis Oncol
Volume : 6
Pages : e2200148

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Année : 2022
Journal : J Cancer Res Clin Oncol
Pages : 1-6

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

Auteurs : Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V
Année : 2022
Journal : Eur J Cancer
Volume : 172
Pages : 340-348

Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].

Auteurs : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Année : 2022
Journal : Eur J Cancer
Volume : 175
Pages : 336-338

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.

Auteurs : Thouvenin J, Van Marcke C, Decoster L, Raicevic G, Punie K, Vandenbulcke M, Salgado R, Van Valckenborgh E, Maes B, Joris S, Steichel DV, Vranken K, Jacobs S, Dedeurwaerdere F, Martens G, Devos H, Duhoux FP, Rasschaert M, Pauwels P, Geboes K, Collignon J, Tejpar S, Canon JL, Peeters M, Rutten A, Van de Mooter T, Vermeij J, Schrijvers D, Demey W, Lybaert W, Van Huysse J, Mebis J, Awada A, Claes KBM, Hebrant A, Van der Meulen J, Delafontaine B, Bempt IV, Maetens J, de Hemptinne M, Rottey S, Aftimos P, De Grève J
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100524

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100501

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.

Auteurs : Tolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 1582

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.

Auteurs : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 2755-2763

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

Auteurs : Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100219

RTK Inhibitors in Melanoma: From Bench to Bedside.

Auteurs : Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem G
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Sarcoidosis Versus Lymphoma?

Auteurs : Dal Lago L, Sarrand J, Woff E, Awada A, Vouche M, Pepersack T
Année : 2021
Journal : Eur J Case Rep Intern Med
Volume : 8
Pages : 002250

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.

Auteurs : Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 3329-3338

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.

Auteurs : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Année : 2021
Journal : Breast
Volume : 57
Pages : 86-94

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Auteurs : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Année : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91

Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.

Auteurs : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Année : 2021
Journal : Mol Cancer Res
Volume : 19
Pages : 1221-1233

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A
Année : 2021
Journal : BMC Cancer
Volume : 21
Pages : 1292

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Auteurs : Najem A, Wouters J, Krayem M, Rambow F, Sabbah M, Sales F, Awada A, Aerts S, Journe F, Marine JC, Ghanem GE
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 780654